TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hightide Therapeutics Inc ( (HK:2511) ) just unveiled an update.
HighTide Therapeutics presented evidence at the ASN Annual Meeting showing that their drug HTD1801 benefits patients with mild renal impairment by improving eGFR trajectory and normalizing renal function. This development highlights HTD1801’s potential as a foundational therapy in CKM disease management, reinforcing the company’s strategic focus on delivering comprehensive treatments for chronic metabolic diseases.
More about Hightide Therapeutics Inc
HighTide Therapeutics, Inc. is a biopharmaceutical company focused on developing multifunctional, multi-targeted therapies for chronic metabolic diseases, particularly addressing cardiovascular-kidney-metabolic (CKM) syndrome. The company has a globally integrated pipeline and has advanced multiple clinical programs, with its lead asset, HTD1801, receiving Fast Track and Orphan Drug designations from the US FDA.
Average Trading Volume: 1,319,895
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$1.78B
For an in-depth examination of 2511 stock, go to TipRanks’ Overview page.